Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	14D0988472	05/04/2021
Name of Provider or Supplier	**Street Address, City, State**	
Doctors Clinical Laboratory	1685 Winnetka Circle, Rolling Meadows, IL	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	**Summary Statement of Deficiencies**
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the CASPER Report 0155D Proficiency Testing (PT) records and communication with the American Association of Bioanalysts (AAB) PT program representative; the laboratory failed to successfully participate in the testing of PT samples for the endocrinology analyte Triiodothyronine (T3) Uptake during events 2 and 3 of 2020 and event 1 of 2021 resulting in non-initial (subsequent-not the first) unsuccessful performance. Findings include: 1. Review of CASPER Report 0155D generated on 05-03-2021 and communication with the AAB PT provider on 05/04

	/2021 at 2:37 PM, confirmed the non-initial (subsequent-not the first) unsuccessful performance for the analyte T3 Uptake under the sub-specialty of endocrinology for PT events 2 and 3 of 2020 and event 1 of 2021. See D2107.
D2107	ENDOCRINOLOGY CFR(s): 493.843(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CASPER Report 0155D Proficiency Testing (PT) records and communication with the PT provider American Association of Bioanalysts (AAB) program representative; the laboratory failed to successfully participate in the testing of the endocrinology analyte Triiodothyronine (T3) Uptake during events 2 and 3 of 2020 and event 1 of 2021, resulting in non-initial (subsequent-not the first) unsuccessful PT performance. Findings include: 1. Review of the CASPER Report 0155D, generated on 05-03-2021, revealed the non-initial (subsequent -not the first) unsuccessful performance for the endocrinology analyte listed below. ENDOCRINOLOGY T3 Uptake - EVENT-2, 2020 = 0% Unsatisfactory T3 Uptake - EVENT-3, 2020 = 0% Unsatisfactory T3 Uptake - EVENT-1, 2021 = 0% Unsatisfactory 2. A phone interview with the (AAB) PT vendor on 05/04/2021 at 2:37 PM, confirmed the unsatisfactory scores for T3 Uptake, under the sub-specialty of endocrinology, for PT events 2 and 3 of 2020 and event 1 of 2021 due to the laboratory's failure to report to the PT program.